Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials.

ABSTRACT:

Background

Two recent, randomized, placebo-controlled phase II/III trials (clinicaltrials.gov: NCT01110720, NCT01049399) of davunetide and tideglusib in progressive supranuclear palsy (PSP) generated prospective, 1-year longitudinal datasets of high-resolution T1-weighted three-dimensional MRI.

Objective

The objective of this study was to develop a quantitative MRI disease progression measurement for clinical trials.

Methods

The authors performed a fully automated quantitative MRI analysis employing atlas-based volumetry and provide sample size calculations based on data collected in 99 PSP patients assigned to placebo in these trials. Based on individual volumes of 44 brain compartments and structures at baseline and 52 weeks of follow-up, means and standard deviatio

SUBMITTER: Hoglinger GU 

PROVIDER: S-EPMC5808453 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature